This week on Prosthetic Gods, Nir and J discuss the tradeoffs of GLP1 drugs. Their use has reversed the obesity epidemic and has proven to have myriad medical and psychological benefits. But they also come with risks, and are seen as a technofix replacing the need for diets. Are GLP1s another step to the posthuman body, and is that a good or bad thing?

Errata: The first GLP1s were approved by the FDA in 2005, semaglutide/Ozempic in 2017, and oral orforglipron/Foundayo was approved in April 2026. More than two thirds of American adults are overweight or obese by BMI, and 40% are obese.

GLP-1s Are a Lot Weirder Than Anyone Thought | The Ezra Klein Show  

Ethical Considerations in the Use of Weight Loss Medications 

The Ethics of Ozempic and Wegovy

WHO issues global guideline on the use of GLP-1 medicines in treating obesity  

Review of 64 studies finds GLP1s effective for weight loss for almost all groups 

Obesity rate declining in US

Hard Fork Podcast

Rest is History Podcast

As always, listeners can contact us at [email protected] with questions, comments, and suggestions for future topics.

Hosted by James Hughes and Nir Eisikovits